ClinicalTrials.gg
RecruitingNCT07127705Updated Aug 17, 2025

Rapid Response of Stem Cells and Immune Cells for Efficacy

An interventional study of Placebo and Chaga Mushroom in Stem Cell Surveillance, sponsored by Natural Immune Systems Inc. Recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-17.

Sponsored by Natural Immune Systems Inc · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The goal for this clinical trial is to compare rapid effects of four products on stem cells, immune activation, and mitochondrial function. A double-blind, placebo-controlled, cross-over study design will be used.

Read the detailed description

This clinical trial aims at documenting acute effects of consuming four products through evaluation of stem cell surveillance and mitochondrial resilience.

Data on stem cell trafficking will be collected. The testing will show whether consuming the products leads to a rapid change in stem cell surveillance. Data on cellular energy production and mitochondrial resilience in white blood cells under oxidative and inflammatory stress ex vivo will be collected. This testing will show whether consuming the test products leads to support of energy production within mitochondria, under normal and stressed conditions.

02

Conditions studied

  • Stem Cell Surveillance
03

In context

Lead sponsor

Natural Immune Systems Inc is the lead sponsor of 25 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adults;
  • Age 18 - 75 years (inclusive);
  • between 18.0 and 34.9 (inclusive);
  • Veins easy to see in one or both arms (to allow for the multiple blood draws);
  • Willing to comply with study procedures, including:

    • Maintaining a consistent diet and lifestyle routine throughout the study,
    • Consistent habit of bland breakfasts on days of clinic visits,
    • Abstaining from exercising and nutritional supplements on the morning of a study visit,
    • Abstaining from use of coffee, tea, and soft drinks for at least one hour prior to a clinic visit;
    • Abstaining from music, candy, gum, computer/cell phone use (airplane mode is allowed), during clinic visits.

Exclusion criteria

Exclusion Criteria:

  • Previous major gastrointestinal surgery (absorption of test product may be altered) (minor surgery not a problem, including previous removal of appendix and gall bladder);
  • Taking anti-inflammatory medications on a daily basis;
  • Currently experiencing intense stressful events/ life changes;
  • Currently in intensive athletic training (such as marathon runners);
  • Currently taking antipsychotic medications such as clozapine, Risperdal, Abilify, Zyprexa or Seroquel;
  • An unusual sleep routine (examples: working graveyard shift, irregular routine with frequent late nights, studying, partying);
  • Unwilling to maintain a constant intake of supplements over the duration of the study;
  • Anxiety about having blood drawn;
  • Pregnant, nursing, or trying to become pregnant;
  • Known food allergies related to ingredients in active test product or placebo.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Crossover group 1, randomized

    Crossover study: Participants consume a test product on each of the five clinic days, at least 1 week apart, allowing for 1 week wash-out period between each product. Participants will consume each of the 4 active test products versus placebo over 5 weeks. The order of interventions for this group is A, C, B, D, E.

    Dietary Supplement: Placebo · Dietary Supplement: Chaga Mushroom · Dietary Supplement: Ginseng extract · Dietary Supplement: Olive extract · Dietary Supplement: Potassium Hydrogen Glucarate

  • Experimental
    Crossover group 2, randomized

    Crossover study: Participants consume a test product on each of the five clinic days, at least 1 week apart, allowing for 1 week wash-out period between each product. Participants will consume each of the 4 active test products versus placebo over 5 weeks. The order of interventions for this group is E, A, C, B, D.

    Dietary Supplement: Placebo · Dietary Supplement: Chaga Mushroom · Dietary Supplement: Ginseng extract · Dietary Supplement: Olive extract · Dietary Supplement: Potassium Hydrogen Glucarate

  • Experimental
    Crossover group 3, randomized

    Crossover study: Participants consume a test product on each of the five clinic days, at least 1 week apart, allowing for 1 week wash-out period between each product. Participants will consume each of the 4 active test products versus placebo over 5 weeks. The order of interventions for this group is D, E, A, C, B.

    Dietary Supplement: Placebo · Dietary Supplement: Chaga Mushroom · Dietary Supplement: Ginseng extract · Dietary Supplement: Olive extract · Dietary Supplement: Potassium Hydrogen Glucarate

  • Experimental
    Crossover group 4, randomized

    Crossover study: Participants consume a test product on each of the five clinic days, at least 1 week apart, allowing for 1 week wash-out period between each product. Participants will consume each of the 4 active test products versus placebo over 5 weeks. The order of interventions for this group is B, C, D, A, E.

    Dietary Supplement: Placebo · Dietary Supplement: Chaga Mushroom · Dietary Supplement: Ginseng extract · Dietary Supplement: Olive extract · Dietary Supplement: Potassium Hydrogen Glucarate

Interventions

  • Dietary supplementPlacebo

    2 capsules

  • Dietary supplementChaga Mushroom

    2 capsules

  • Dietary supplementAsian ginsengStudies of Asian ginsengAsian ginseng pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    2 capsules

  • Dietary supplementOlive extract

    2 capsules

  • Dietary supplementPotassium Hydrogen Glucarate

    2 capsules

06

What researchers measure

Primary outcomes

  1. Stem cell trafficking

    Changes to the number of stem cells in the blood circulation (number of cells per mL blood). Data is collected on the following types of stem cells: CD45dimCD34+CD309+, CD45dimCD34+CD309-, CD31++CD34-, CD45-CD90+.

    Time frame: Baseline. 1 hour, 2 hours, and 3 hours after ingestion of study drug

Secondary outcomes

  1. Mitochondrial volume per cell

    Mitochondrial volume per cell under unstressed, oxidative stress, and inflammatory stress ex vivo. White blood cells are purified and cultured ex vivo in unstressed versus inflamed culture conditions. The mitochondrial reporter dye MitoTracker is used to obtain relative measures of mitochondrial volume per cell using flow cytometry, where the mean fluorescence intensity (MFI) is quantified on lymphocytes, monocytes, and PMN cells.

    Time frame: Baseline. 1 hour, 2 hours, 3 and hours after ingestion of study drug

  2. Mitochondrial membrane potential per cell

    Cellular energy production under unstressed, oxidative stress, and inflammatory stress ex vivo. White blood cells are purified and cultured ex vivo in unstressed versus inflamed culture conditions. The mitochondrial reporter dye JC-1 is a fluorescent cationic dye used to obtain relative measures of mitochondrial membrane potential per cells, using flow cytometry, where the mean fluorescence intensity (MFI) is quantified on lymphocytes, monocytes, and PMN cells.

    Time frame: Baseline. 1 hour, 2 hours, and 3 hours after ingestion of study drug

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Aug 2025, 3 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2025
First posted
Aug 17, 2025
StartActual
May 21, 2025
Primary completionEst.
Aug 27, 2025
CompletionEst.
Oct 3, 2025
Last update
Aug 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07127705
Lead sponsor
Natural Immune Systems Inc
Collaborators
Applied Food Sciences Inc.
Responsible party
Sponsor
First posted
Aug 17, 2025
Start date
May 21, 2025
Primary completion
Aug 27, 2025 (estimated)
Completion
Oct 3, 2025 (estimated)
Last update
Aug 17, 2025

Study contacts

Gitte S. Jensen, PhD
Contact
Gitte@nislabs.com
5418820112
Alex Cruickshank
Contact

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Asian ginseng

Start the discussion